Skip to main content
PRQR
NASDAQ Life Sciences

ProQR Announces Positive Phase 1 Data for AX-0810, Validating Axiomer RNA Editing Platform

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.91
Mkt Cap
$190.704M
52W Low
$1.33
52W High
$3.1
52W Position info
44% above low
Off High info
38% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRQR sits 44% above its 52-week low of $1.33.

Summary

ProQR Therapeutics reported positive Phase 1 clinical data for AX-0810, demonstrating dose-dependent target engagement and a favorable safety profile, marking the first clinical validation of its Axiomer RNA editing platform.


Key Events · Product Development and Regulatory · PRQR

  • Positive Phase 1 Data for AX-0810

    The company announced positive target engagement data from its ongoing Phase 1 study of AX-0810, demonstrating dose-dependent increases in total bile acids (up to 8-fold) and a favorable safety and tolerability profile with no serious adverse events.

  • Axiomer Platform Clinically Validated

    This data establishes the first clinical validation of ProQR's proprietary Axiomer RNA editing technology platform, a significant de-risking event for the company's core technology.

  • NTCP Franchise Advancement

    The positive results support the advancement of the NTCP franchise, including a next-generation candidate AX-0811, with a Clinical Trial Application (CTA) filing expected in mid-2026 and initial human data by year-end 2026. Biliary atresia has been selected as the initial indication for Phase 2 development.

  • Future Milestones Outlined

    ProQR provided a roadmap for its NTCP franchise, including an investigator-initiated trial (IIT) in pediatric biliary atresia in China (initial data H1 2027) and a potentially registration-enabling Phase 2 program starting mid-2027. Other pipeline candidates also have upcoming CTA filings and initial data readouts anticipated in 2027.


Analysis · PRQR · Life Sciences

This filing is highly important as it provides the first clinical validation of ProQR's proprietary Axiomer RNA editing platform, a critical de-risking event for a clinical-stage biotechnology company. The positive Phase 1 data for AX-0810, showing strong target engagement and a favorable safety profile, supports the advancement of its NTCP franchise and provides a clear development path towards a potentially registration-enabling Phase 2 program. This news could significantly boost investor confidence, especially following recent capital raises and shareholder activity.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRQR was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.7M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRQR - Latest Insights

PRQR
Sep 09, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.05
Real-time Price: $1.33 info
Change: -$0.720 (-35%) info
Market Cap: $184.869M info
PRQR
Aug 13, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.33 info
Change: -$0.580 (-30%) info
Market Cap: $184.869M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.33 info
Change: -$0.5208 (-28%) info
Market Cap: $184.869M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.33 info
Change: -$0.580 (-30%) info
Market Cap: $184.869M info
PRQR
Aug 03, 2026, 4:01 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.77
Real-time Price: $1.33 info
Change: -$0.440 (-25%) info
Market Cap: $184.869M info